or Try an Advanced Search...

    Cell Product Stocks List

    Symbol Grade Name % Change
    MESO B Mesoblast Limited -1.94
    SGMO C Sangamo BioSciences, Inc. -1.79
    CLLS D Cellectis S.A. -2.95
    BCLI F Brainstorm Cell Therapeutics Inc. 0.79
    NTLA F Intellia Therapeutics, Inc. 5.95
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biotechnology Adult Stem Cell Biology Blastoma Bone Bone Marrow Chimeric Antigen Receptor Emerging Technologies Glioblastoma Life Sciences Medicine Molecular Biology Stem Cell Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Adoptive Cell Transfer Amyloid Amyloidosis Amyotrophic Lateral Sclerosis Antitrypsin Deficiency

    Related ETFs - A few ETFs which own one or more of the above listed Cell Product stocks.

    Symbol Grade Name Weight
    GNOM F Global X Genomics & Biotechnology ETF 4.22
    ARKG F ARK Genomic Revolution Multi-Sector ETF 3.89
    ARKK B ARK Innovation ETF 2.09
    HRTS D Tema Cardiovascular and Metabolic ETF 1.66
    CANC D Tema Oncology ETF 1.58
    View all Cell Product ETFs...
    Compare ETFs
    Compare ARKG to HRTS Compare GNOM to ARKG Compare GNOM to ARKK

        Cell Product Stocks Recent News

        Date Stock Title
        Nov 19 SGMO Sangamo stock climbs 12% post-market on FDA update for ST-503
        Nov 19 SGMO Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
        Nov 19 NTLA Intellia Therapeutics Announces Promising CRISPR Therapy Results
        Nov 19 NTLA ReCode to secure funds for cystic fibrosis gene correction treatments
        Nov 19 NTLA Intellia Therapeutics price target lowered to $70 from $80 at Wells Fargo
        Nov 19 NTLA Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)
        Nov 18 NTLA Intellia’s gene editing therapy shows early potential in rare heart condition
        Nov 18 NTLA CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest
        Nov 16 NTLA Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
        Nov 15 SGMO Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations
        Related Industries: Biotechnology
        Related Stock Lists: Biotechnology Adult Stem Cell Biology Blastoma Bone Bone Marrow Chimeric Antigen Receptor Emerging Technologies Glioblastoma Life Sciences Medicine Molecular Biology Stem Cell Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Adoptive Cell Transfer Amyloid Amyloidosis Amyotrophic Lateral Sclerosis Antitrypsin Deficiency
        Cell Product

        Cell product is a term used to describe the process of producing a product from a cell culture. This process involves culturing cells in a laboratory setting and then harvesting the cells to create a product. Cell products can range from pharmaceuticals and biologics to food and cosmetics.

        Browse All Tags